Breast cancer

Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition

Volumn , Issue , 2017, Pages 861-888

  Brinton, Louise A ^a   Gaudet, Mia M ^b   Gierach, Gretchen L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

Breast cancer; Cell division; Genetic; Hormones; Ovary

Indexed keywords

EID: 85051043331     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oso/9780190238667.003.0045     Document Type: Chapter

References (334)

1. Ades F, Zardavas D, Bozovic-Spasojevic I, et al. 2014. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol, 32(25), 2794-2803 .PMID: 25049332.
2. Ahlgren M, Melbye M, Wohlfahrt J, and Sorensen TI. 2004. Growth patterns and the risk of breast cancer in women. N Engl J Med, 351(16), 1619-1626 .PMID: 15483280.
3. Alexander DD, Morimoto LM, Mink PJ, and Lowe KA. 2010. Summary and meta-analysis of prospective studies of animal fat intake and breast cancer. Nutr Res Rev, 23(1), 169-179 .PMID: 20181297.
4. Ali S, and Coombes RC, 2002. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer, 2(2), 101-112 .PMID: 12635173.
5. Allred DC. 2011. Molecular biomarkers of risk in premalignancy and breast cancer prevention. Cancer Prev Res (Phila), 4(12), 1947-1952 .PMID: 22144468.
6. Amadou A, Ferrari P, Muwonge R, et al. 2013. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev, 14(8), 665-678 .PMID: 23615120.
7. Ambrosone CB, Zirpoli G, Hong CC, et al. 2015. Important role of menar- che in development of estrogen receptor-negative breast cancer in African American women. J Natl Cancer Inst, 107(9), djv172 .PMID: 26085483.
8. Amir E, Freedman OC, Sernga B, and Evans DG. 2010. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst, 102(10), 680-691 .PMID: 20427433.
9. Anderson WF, Rosenberg PS, Prat A, Perou CM, and Sherman ME. 2014. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst, 106(8) .PMCID: PMC4148600.
10. Antoniou A, Pharoah PD, Narod S, et al. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 72(5), 1117-1130 .PMCID: PMC1180265.
11. Antoniou AC, Pharoah PD, McMullan G, et al. 2002. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer, 86(1), 76-83 .PMCID: PMC2746531.
12. Antoniou AC, Wang X, Fredericksen ZS, et al. 2010. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet, 42(10), 885-892 .PMCID: PMC3130795.
13. Arpino G, Milano M, and De Placido S. 2015. Features of aggressive breast cancer. Breast, 24(5), 594-600 .PMID: 26144637.
14. Baer HJ, Collins LC, Connolly JL, et al. 2009. Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies., 115(7), 1404-1411 .PMCID: PMC2661011.
15. Bakken K, Fournier A, Lund E, et al. 2011. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer, 128(1), 144-156 .PMID: 20232395.
16. Bambhroliya A, Chavez-MacGregor M, and Brewster AM. 2015. Barriers to the use of breast cancer risk reduction therapies. J Natl Comp Cancer Network, 13(7), 927-935 .PMID: 26150584.
17. Bardia A, Keenan TE, Ebbert JO, et al. 2016. Personalizing aspirin use for targeted breast cancer chemoprevention in postmenopausal women. Mayo Clin Proc, 91(1), 71-80 .PMCID: PMC4807132.
18. Barlow WE, White E, Ballard-Barbash R, et al. 2006. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst, 98(17), 1204-1214 .PMID: 16954473.
19. Barnard ME, Boeke CE, and Tamimi RM. 2015. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta, 1856(1), 73-85 .PMID: 26071880.
20. Barry JA, Azizia MM, and Hardiman PJ. 2014. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Rep rod Update, 20(5), 748-758 .PMCID: PMC4326303.
21. Beaber EF, Buist DS, Barlow WE, et al. 2014a. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res, 74(15), 4078-089 .PMCID: PMC4154499.
22. Beaber EF, Malone KE, Tang MT, et al. 2014b. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev, 23(5), 755-764 .PMCID: PMC4032363.
23. Beck AH, Sangoi AR, Leung S, et al. 2011. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med, 3(108), 108-113 .PMID: 22072638.
24. Becker S, and Kaaks R. 2009. Exogenous and endogenous hormones, mam- mographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk? Recent Results Cancer Res, 181, 135-157 .PMID: 19213565.
25. Begg C, and Zhang Z. 1994. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev, 3(2), 173-175 .PMID: 8049640.
26. Beral V, Reeves G, Bull D, Green J, and Million Women Study C. 2011. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst, 103(4), 296-305 .PMCID: PMC3039726.
27. Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, and Thompson WD. 2003. The descriptive epidemiology of second primary breast cancer. Epidemiology, 14(5), 552-558 .PMID: 14501270.
28. Bertrand KA, Scott CG, Tamimi RM, et al. 2015. Dense and nondense mammographic area and risk of breast cancer by age and tumor char-acteristics. Cancer Epidemiol Biomarkers Prev, 24(5), 798-809 .PMCID: PMC4417380.
29. Bethea TN, Rosenberg L, Hong CC et al. 2015. A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium. Breast Cancer Res, 17, 22 .PMCID: PMC4358874.
30. Bombonati A, and Sgroi DC. 2011. The molecular pathology of breast cancer progression. J Pathol, 223(2), 307-317 .PMCID: PMC3069504.
31. Boyd N, Dite G, Stone J, et al. 2002. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med, 347, 886-894 .PMID: 12239257.
32. Boyd N, Guo H, Martin L, et al. 2007. Mammographic density and the risk and detection of breast cancer. N Engl J Med, 356(3), 227-236 .PMID: 17229950.
33. Boyd NF, Melnichouk O, Martin LJ, et al. 2011. Mammographic density, response to hormones, and breast cancer risk. J Clin Oncol, 29(22), 2985-2992 .PMID: 21709206.
34. Brand JS, Li J, Humphreys K, et al. 2015. Identification of two novel mam-mographic density loci at 6Q25.1. Breast Cancer Res, 17(1), 75 .PMCID: PMC4501298.
35. Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, and Roddam AW. 2010. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol, 11(6), 530-542 .PMCID: PMC3113287.
36. Brinton LA, Cook MB, McCormack V, et al. 2014a. Anthropometric and hor-monal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst, 106(3), djt465 .PMCID: PMC3975166.
37. Brinton LA, Figueroa JD, Awuah B, et al. 2014b. Breast cancer in Sub-Saharan Africa: opportunities for prevention. Breast Cancer Res Treat, 144(3), 467-478 .PMCID: PMC4023680.
38. Brinton LA, Key TJ, Kolonel LN, et al. 2015. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol, 33(18), 2041 PMCID: PMC4461805.
39. Brinton LA, Richesson D, Leitzmann MF, et al. 2008. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev, 17(11), 3150-3160 .PMCID: PMC2755180.
40. Brinton LA, Scoccia B, Moghissi KS, et al. 2014c. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev, 23(4), 584-593 .PMCID: PMC3979528.
41. Brophy JT, Keith MM, Watterson A, et al. 2012. Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case-control study. Environ Health, 11, 87 .PMCID: PMC3533941.
42. Cai Q, Zhang B, Sung H, et al. 2014. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet, 46(8), 886-890 .PMCID: PMC4127632.
43. Calle EE, Feigelson HS, Hildebrand JS, et al. 2009. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer, 115(5), 936-945 .PMID: 19156895.
44. Calle EE, and Kaaks R. 2004. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 4(8), 579-591 .PMID: 15286738.
45. Canchola AJ, Anton-Culver H, Bernstein L, et al. 2012. Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control, 23(3), 473-485 .PMCID: PMC3366039.
46. Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, and Bacchi CE. 2014. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health, 14, 102 .PMCID: PMC4153008.
47. Cecchini R, Costantino JP, Cauley JA, et al. 2012. Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP Study of Tamoxifen and Raloxifene (STAR). Cancer Prev Res (Phila), 5(11), 1321-1329 .PMCID: PMC4131535.
48. Chan DS, Vieira AR, Aune D, et al. 2014. Body mass index and survival in women with breast cancer: systematic literature review and metaanalysis of 82 follow-up studies. Ann Oncol, 25(10): 1901-1914 .PMCID: PMC4176449.
49. Chen C, Ma X, Zhong M, and Yu Z. 2010. Extremely low-frequency electro-magnetic fields exposure and female breast cancer risk: a meta-analysis based on 24,338 cases and 60,628 controls. Breast Cancer Res Treat, 123(2), 569-576 .PMID: 20145992.
50. Chen F, Chen GK, Millikan RC, et al. 2011. Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet, 20(22), 4491-503 .PMCID: PMC3196889.
51. Chen FY, Ou HY, Wang SM, et al. 2013. Associations between body mass index and molecular subtypes as well as other clinical characteristics of breast cancer in Chinese women. Ther Clin Risk Manag, 9, 131-137 .PMCID: PMC3617914.
52. Chen J, Pee D, Ayyagari R, et al. 2006. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst, 98(17), 1215-1226 .PMID: 16954474.
53. Chen L, Malone KE, and Li CI. 2014. Bra wearing not associated with breast cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev, 23(10), 2181-2185 .PMCID: PMC4184992.
54. Chlebowski RT. 2014. Current concepts in breast cancer chemoprevention. Pol Arch Med Wewn, 124(4), 191-199 .PMID: 24618912.
55. Chlebowski RT, Chen Z, Cauley JA, et al. 2010. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol, 28(22), 3582-3590 .PMCID: PMC2917313.
56. Chlebowski RT, Manson JE, Anderson GL, et al. 2013. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst, 105(8), 526-535 .PMCID: PMC3691942.
57. Clevenger CV, Furth PA, Hankinson SE, and Schuler LA. 2003. The role of prolactin in mammary carcinoma. Endocr Rev, 24(1), 1-27 .PMCID: PMC1698952.
58. Cohen SS, Matthews CE, Bradshaw PT, et al. 2013. Sedentary behavior, physical activity, and likelihood of breast cancer among Black and White women: a report from the Southern Community Cohort Study. Cancer Prev Res (Phila), 6(6), 566-576 .PMCID: PMC3703619.
59. Colditz GA, and Bohlke K. 2014. Priorities for the primary prevention of breast cancer. CA Cancer J Clin, 64(3), 186-194 .PMCID: PMC24647877.
60. Colditz GA, Bohlke K, and Berkey CS. 2014. Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res Treat, 145(3), 567-579 .PMCID: PMC4079839.
61. Collaborative Group on Hormonal Factors in Breast Cancer. 1996. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet, 347(9017), 1713-1727 .PMID: 8656904.
62. Collaborative Group on Hormonal Factors in Breast Cancer. 2002. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet, 360(9328), 187-195 .PMID: 12133652.
63. Collaborative Group on Hormonal Factors in Breast Cancer. 2012. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol, 13(11), 1141-1151 .PMCID: PMC3488186.
64. Collins LC, Baer HJ, Tamimi RM et al. 2006. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study., 107(6), 1240-1247. PMID: 16902983.
65. Cook NR, Lee IM, Gaziano JM, et al. 2005. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA, 294(1), 47-55 .PMID: 15998890.
66. Costantino JP, Gail MH, Pee D, et al. 1999. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst, 91(18), 1541-1548 .PMID: 10491430.
67. Crowe FL, Key TJ, Allen NE, et al. 2011. A cross-sectional analysis of the asso-ciations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Hum Biol, 38(2), 194-202 .PMID: 20731527.
68. Cummings SR, Tice JA, Bauer S, et al. 2009. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst, 101(6), 384-398 .PMCID: PMC2720698.
69. Cust AE, Stocks T, Lukanova A, et al. 2009. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat, 113(3), 567-576 .PMID: 18330696.
70. Cuzick J, Sestak I, Bonanni B, et al. 2013. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet, 381(9880), 1827-1834 .PMCID: PMC3671272.
71. Cuzick J, Sestak I, Cawthorn S, et al. 2015. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol, 16(1), 67-75 .PMCID: PMC4772450.
72. Cuzick J, Sestak I, Forbes JF, et al. 2014. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 383(9922), 1041-1048 .PMID: 24333009.
73. Cuzick J, Warwick J, Pinney E, et al. 2011. Tamoxifen-i nduced reduction in mammographic density and breast cancer risk reduction: a nested case- control study. J Natl Cancer Inst, 103, 744-752 .PMID: 21483019.
74. Dallal CM, Brinton LA, Matthews CE, et al. 2016. Association of active and sedentary behaviors with postmenopausal estrogen metabolism. Med Sci Sports Exerc, 48(3), 439-448 .PMCID: PMC4861700.
75. Dallal CM, Tice JA, Buist DS, et al. 2014. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT. Carcinogenesis, 35(2), 346-355 .PMCID: PMC3908751.
76. Davies KR, Cantor SB, and Brewster AM. 2015. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. Int J Womens Health, 7, 181-187 .PMCID: PMC4324540.
77. De Stavola BL, dos Santos Silva I, McCormack V, et al. 2004. Childhood growth and breast cancer. Am J Epidemiol, 159(7), 671-682 .PMID: 15033645.
78. Dearth RK, Delgado DA, Hiney JK, et al. 2010. Parity-induced decrease in systemic growth hormone alters mammary gland signaling: a potential role in pregnancy protection from breast cancer. Cancer Prev Res (Phila), 3(3), 312-321 .PMCID: PMC2833223.
79. Degnim AC, Visscher DW, Berman HK, et al. 2007. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol, 25(19), 2671-2677 .PMID: 17563394.
80. Desai P, Lehman A, Chlebowski RT, et al. 2015. Statins and breast cancer stage and mortality in the Women's Health Initiative. Cancer Causes Control, 26(4), 529-539 .PMID: 25736184.
81. Dieci MV, Orvieto E, Dominici M, Conte P, and Guarneri V. 2014. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist, 19(8), 805-813 .PMCID: PMC4122475.
82. Dong JY, and Qin LQ. 2011. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat, 125(2), 315-323 .PMID: 21113655.
83. Dorgan JF, Stanczyk FZ, Egleston BL, et al. 2009. Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk. J Natl Cancer Inst, 101(21), 1501-1509 .PMCID: PMC2773186.
84. Dossus L, Boutron-Ruault MC, Kaaks R, et al. 2014. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer, 134(8), 1871-1888 .PMID: 24590452.
85. Dupont WD, and Page DL. 1985. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med, 312(3), 146-151 .PMID: 3965932.
86. Easton DF. 1999. How many more breast cancer predisposition genes are there? Breast Cancer Res, 1(1), 14-17 .PMCID: PMC138504.
87. Easton DF, Pharoah PD, Antoniou AC, et al. 2015. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med, 372(23), 2243-2257 .PMCID: PMC4610139.
88. Eliassen AH, Spiegelman D, Xu X, et al. 2011. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res, 72(3), 696-706 .PMCID: PMC3271178.
89. Erbas B, Provenzano E, Armes J, and Gertig D. 2006. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat, 97(2), 135-144 .PMID: 16319971.
90. Fachal L, and Dunning AM. 2015. From candidate gene studies to GWAS and post-GWAS analyses in breast cancer. Curr Opin Genet Dev, 30, 32-41 .PMID: 25727315.
91. Falk RT, Brinton LA, Dorgan JF, et al. 2013. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res, 15(2), R34 .PMCID: PMC4053199.
92. Falk RT, Xu X, Keefer L, Veenstra TD, and Ziegler RG. 2008. A liquid chroma-tography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev, 17(12), 3411-3418 .PMCID: PMC4158914.
93. Familial Breast Cancer Working Group. 2001. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet, 358(9291), 1389-1399 .PMID: 11705483.
94. Farhat GN, Cummings SR, Chlebowski RT, et al. 2011. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst, 103(7), 562-570 .PMCID: PMC3071353.
95. Feng Y, Stram DO, Rhie SK, et al. 2014. A comprehensive examination of breast cancer risk loci in African American women. Hum Mol Genet, 23(20), 5518-5526 .PMCID: PMC4168823.
96. Ferlay J, Soerjomataram I, Dikshit R, et al. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136(5), E359-386 .PMID: 25220842.
97. Figueroa JD, Pfeiffer RM, Brinton LA, et al. 2016. Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease among women with benign breast disease; a nested case-control study. Breast Cancer Res, 159(1), 13-172 .PMID: 27488681.
98. Figueroa JD, Pfeiffer RM, Patel DA, et al. 2014. Terminal duct lobular unit involution of the normal breast: implications for breast cancer etiology. J Natl Cancer Inst, 106(10), dju286 .PMCID: PMC4200067.
99. Fischer C, Kuchenbacker K, Engel C, et al. 2013. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet, 50(6), 360-367 .PMID: 23564750.
100. Fitzgibbons PL, Henson DE, and Hutter RV. 1998. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med, 122(12), 1053-1055 .PMID: 98708652.
101. Fontein DB, de Glas NA, Duijm M, et al. 2013. Age and the effect of physical activity on breast cancer survival: a systematic review. Cancer Treat Rev, 39(8), 958-965 .PMID: 23608116.
102. Fournier A, Dos Santos G, Guillas G, et al. 2014. Recent recreational physical activity and breast cancer risk in postmenopausal women in the E3N cohort. Cancer Epidemiol Biomarkers Prev, 23(9), 1893-1902 .PMID: 25114017.
103. Freedman AN, Yu B, Gail MH, et al. 2011. Benefit/risk assessment for breast can-cer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol, 29(17), 2327-2333 .PMCID: PMC3107748.
104. Fuhrman BJ, Schairer C, Gail MH, et al. 2012. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst, 104(4), 326-339 .PMCID: PMC3283536.
105. Fuhrman BJ, Xu X, Falk RT, et al. 2014. Assay reproducibility and interindivid-ual variation for 15 serum estrogens and estrogen metabolites measured by liquid chromatography-tandem mass spectrometry. Cancer Epidemiol Biomarkers Prev, 23(12), 2649-2657 .PMCID: PMC4289148.
106. Gail MH. 2008. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst, 100(14), 1037-1041 .PMCID: PMC2528005.
107. Gail MH, Costantino JP, Pee D, et al. 2007. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst, 99(23), 1782-1792 .PMID: 18042936.
108. Gandini S, Puntoni M, Heckman-Stoddard BM, et al. 2014. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila), 7(9), 867-885 .PMCID: PMC4154969.
109. Garcia-Closas M, Gunsoy NB, and Chatterjee N. 2014. Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. J Natl Cancer Inst, 106(11) .PMCID: PMC4271030.
110. Garcia-Esquinas E, Guino E, Castano-Vinyals G, et al. 2016. Association of diabetes and diabetes treatment with incidence of breast cancer. Acta Diabetol, 53(1), 99-107 .PMCID: PMC4749645.
111. Gaudet MM, Carter BD, Patel AV, et al. 2014a. Waist circumference, body mass index, and postmenopausal breast cancer incidence in the Cancer Prevention Study-II Nutrition Cohort. Cancer Causes Control, 25(6), 737-745 .PMID: 24715420.
112. Gaudet MM, Gapstur SM, Sun J, et al. 2013a. Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst, 105(8), 515-525 .PMID: 23449445.
113. Gaudet MM, Gapstur SM, Sun J, et al. 2014b. Oophorectomy and hysterectomy and cancer incidence in the Cancer Prevention Study-II Nutrition Cohort. Obstet Gynecol, 123(6), 1247-1255 .PMID: 24807324.
114. Gaudet MM, Patel AV, Sun J, Teras LR, and Gapstur SM. 2013b. Tubal ster-ilization and breast cancer incidence: results from the cancer prevention study II nutrition cohort and meta-analysis. Am J Epidemiol, 177(6), 492-499 .PMID: 23416445.
115. Gaudet MM, Patel AV, Teras LR, et al. 2013c. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet, 4(3), 156-166 .PMCID: PMC3773567.
116. Gaudet MM, Press MF, Haile RW, et al. 2011. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat, 130(2), 587-597 .PMCID: PMC3721192.
117. Gertig DM, Stillman IE, Byrne C et al. 1999. Association of age and reproductive factors with benign breast tissue composition. Cancer Epidemiol Biomarkers Prev, 8(10), 873-879 .PMID: 10548315.
118. Ghosh K, Hartmann LC, Reynolds C, et al. 2010a. Association between mam- mographic density and age-related lobular involution of the breast. J Clin Oncol, 28(13), 2207-2212 .PMCID: PMC2860438.
119. Ghosh K, Vachon CM, Pankratz VS, et al. 2010b. Independent association of lobular involution and mammographic breast density with breast cancer risk. J Natl Cancer Inst, 102(22), 1716-1723 .PMCID: PMC2982810.
120. Gierach GL, Brinton LA, and Sherman ME. 2010. Lobular involution, mam- mographic density, and breast cancer risk: visualizing the future? J Natl Cancer Inst, 102(22), 1685-1687 .PMCID: PMC2982811.
121. Gierach GL, Curtis RE, Pfeiffer RM, et al. 2017. Association of adjuvant tamoxifen and aromatase inhibitor therapy with contralateral breast cancer risk among US women with breast cancer in a general community setting. JAMA Oncol, 3(2):186-193 .PMID: 27711920.
122. Gierach GL, Geller BM, Shepherd JA, Patel DA, Vacek PM, Weaver DL, et al. 2014. Comparison of mammographic density assessed as volumes and areas among women undergoing diagnostic image-guided breast biopsy. Cancer Epidemiol Biomarkers Prev, 23(11), 2338-2348.
123. Gierach GL, Patel DA, Pfeiffer RM, et al. 2016. Relationship of terminal duct lobular unit involution of the breast with area and volume mammographic densities. Cancer Prev Res, 9(2), 149-158 .PMCID: PMC4784982.
124. Gierach GL, Yang XR, Figueroa JD, and Sherman ME. 2013. Emerging concepts in breast cancer risk prediction. Curr Obstet Gynecol Rep, 2(1), 43-52 .PMCID: PMC4262133.
125. Ginsburg OM, Martin LJ, and Boyd NF. 2008. Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer, 99, 1369-1374 .PMCID: PMC2579686.
126. Global Burden of Disease Cancer. 2015. The global burden of cancer 2013. JAMA Oncol, 1(4), 505-527 .PMCID: PMC4500822.
127. Goss PE, Ingle JN, Ales-Martinez JE, et al. 2011. Exemestane for breast- cancer prevention in postmenopausal women. N Engl J Med, 364(25), 2381-2391 .PMID: 21639806.
128. Gottschau M, Kjaer SK, Jensen A, Munk C, and Mellemkjaer L. 2015. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol, 136(1), 99-103 .PMID: 25451694.
129. Green J, Cairns BJ, Casabonne D, et al. 2011. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol, 12(8), 785-794 .PMCID: PMC3148429.
130. Grenier D, Cooke AL, Lix L, et al. 2011. Bone mineral density and risk of postmenopausal breast cancer. Breast Cancer Res Treat, 126(3), 679-686 .PMID: 20838879.
131. Gunter MJ, Hoover DR, Yu H, et al. 2009. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst, 101(1), 48-60 .PMCID: PMC2639294.
132. Gunter MJ, Wang T, Cushman M, et al. 2015. Circulating adipokines and inflammatory markers and postmenopausal breast cancer risk. J Natl Cancer Inst, 107(9), djv169 .PMCID: PMC4651104.
133. Guo J, Huang Y, Yang L, et al. 2015. Association between abortion and breast cancer: an updated systematic review and meta-analysis based on prospective studies. Cancer Causes Control, 26(6), 811-819 .PMID: 25779378.
134. Guo YP, Martin LJ, Hanna W, et al. 2001. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev, 10(3), 243-248 .PMID: 11303594.
135. Gupta V, Carey JL, Kawakubo H, et al. 2005. Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci U S A, 102(9), 3219-3224 .PMCID: PMC552936.
136. Hankinson SE, and Eliassen AH. 2007. Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol, 106(1-5), 24-30 .PMCID: PMC2715949.
137. Harris HR, Willett WC, Terry KL, and Michels KB. 2011. Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. J Natl Cancer Inst, 103(3), 273-278 .PMCID: PMC3107569.
138. Hartmann LC, Radisky DC, Frost MH et al. 2014. Understanding the prema- lignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila), 7(2), 211-217 .PMCID: PMC4167687.
139. Hartmann LC, Sellers TA, Frost MH, et al. 2005. Benign breast disease and the risk of breast cancer. N Engl J Med, 353(3), 229-237 .PMID: 16034008.
140. He C, Anand ST, Ebell MH, Vena JE, and Robb SW. 2015. Circadian disrupting exposures and breast cancer risk: a meta-analysis. Int Arch Occup Environ Health, 88(5), 533-547 .PMID: 25261318.
141. Healy GN, Matthews CE, Dunstan DW, Winkler EA, and Owen N. 2011. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06. Eur Heart J, 32(5), 590-597 .PMCID: PMC3634159.
142. Hildebrand JS, Gapstur SM, Campbell PT, Gaudet MM, and Patel AV. 2013. Recreational physical activity and leisure-time sitting in relation to post-menopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev, 22(10), 1906-1912 .PMID: 24097200.
143. Hoover RN. 2012. That recognised risk factors can explain past and present international differences in breast cancer incidence: misconceptions 5. Br J Cancer, 107(3), 408-10 .PMCID: PMC3405203.
144. Hoover RN, Hyer M, Pfeiffer RM, et al. 2011. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med, 365(14), 1304-1314 .PMID: 21991952.
145. Horn J, Opdahl S, Engstrom MJ, et al. 2014. Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women. Cancer Causes Control, 25(7), 881-889 .PMID: 24789514.
146. Horne HN, Sherman ME, Pfeiffer RM et al. 2016. Circulating insulinlike growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Res, 18(1), 24 .PMCID: PMC4758090.
147. Howell A, Anderson AS, Clarke RB, et al. 2014. Risk determination and preven-tion of breast cancer. Breast Cancer Res, 16(5), 446 .PMCID: PMC4303126.
148. Howlader N, Altekruse SF, Li CI, et al. 2014. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst, 106(5), dju055 .PMCID: PMC459-552.
149. Hunter DJ, Colditz GA, Hankinson SE, et al. 2010. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev, 19(10), 2496-2502 .PMCID: PMC3055790.
150. Huo CW, Chew GL, Britt KL, et al. 2014. Mammographic density: a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat, 144(3), 479-502 .PMID: 24615497.
151. Ingber SZ, Buser MC, Pohl HR, et al. 2013. DDT/DDE and breast cancer: a meta-analysis. Regul Toxicol Pharmacol, 67(3), 421-433 .PMID: 24021539.
152. Islam T, Matsuo K, Ito H, et al. 2012. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. Ann Oncol, 23(9), 2435-2441 .PMID: 22328736.
153. Jacob P, and Stram DO. 2013. Late health effects of radiation exposure: new statistical, epidemiological, and biological approaches. Int J Radiat Biol, 89(8), 673-683 .PMID: 23402349.
154. James RE, Lukanova A, Dossus L, et al. 2011. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Red (Phila), 4(10), 1626-1635 .PMID: 21813404.
155. Jatoi I, and Anderson WF. 2010. Qualitative age interactions in breast cancer studies: a mini-review. Future Oncol, 6(11), 1781-1788 .PMID: 21142663.
156. Jemal A, Bray F, Center MM, et al. 2011. Global cancer statistics. CA Cancer J Clin, 61(2), 69-90 .PMID: 21296855.
157. Jenkins EO, Deal AM, Anders CK, et al. 2014. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist, 19(10), 1076-1083 .PMCID: PMC4200998.
158. John EM, Phipps AI, Davis A, and Koo J. 2005. Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiol Biomarkers Prev, 14(12), 2905-2913 .PMID: 16365008.
159. John EM, Sangaramoorthy M, Hines LM, et al. 2015. Overall and abdominal adiposity and premenopausal breast cancer risk among Hispanic women: the breast cancer health disparities study. Cancer Epidemiol Biomarkers Prev, 24(1), 138-147 .PMCID: PMC4294975.
160. Jung S, Spiegelman D, Baglietto L, et al. 2013. Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst, 105(3), 219-236 .PMCID: PMC3593764.
161. Kabat GC, Xue X, Kamensky V, et al. 2015. Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. Cancer Causes Control, 26(2), 219-229 .PMID: 25430815.
162. Kaiser JC, Jacob P, Meckbach R, and Cullings HM. 2012. Breast cancer risk in atomic bomb survivors from multi-model inference with incidence data 1958-1998. Radiat Environ Biophys, 51(1), 1-14 .PMID: 21947564.
163. Kent C, Horton J, Blitzblau R, and Koontz BF. 2015. Whose disease will recur after mastectomy for early stage, node-negative breast cancer? A systematic review. Clin Breast Cancer, 15(6), 403-412 .PMID: 26198331.
164. Kerlikowske K, Ichikawa L, Miglioretti DL, et al. 2007. Longitudinal measure-ment of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst, 99(5), 386-395 .PMID: 17341730.
165. Keum N, Greenwood DC, Lee DH, et al. 2015. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst, 107(2), djv088 .PMID: 25757865.
166. Key T, Appleby P, Barnes I, et al. 2002. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst, 94(8), 606-616 .PMID: 11959894.
167. Key TJ, Appleby PN, Reeves GK, et al. 2011. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer, 105(5), 709-722 .PMCID: PMC3188939.
168. Key TJ, Appleby PN, Reeves GK, et al. 2013. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol, 14(10), 1009-1019 .PMID: 23890780.
169. Khodr ZG, Sherman ME, Pfeiffer RM, et al. 2014. Circulating sex hormones and terminal duct lobular unit involution of the normal breast. Cancer Epidemiol Biomarkers Prev, 23(12), 2765-2773 .PMCID: PMC4333643.
170. Kim J, Han W, Moon H-G, et al. 2012. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res, 14(4), R102 .PMCID: PMC3680951.
171. Ko KL, Shin IS, You JY, et al. 2013. Adjuvant tamoxifen-t nduced mammo- graphic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients. Breast Cancer Res Treat, 142(3), 559-567 .PMID: 24233999.
172. Kurian AW, McClure LA, John EM, et al. 2009. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst, 101(15), 1058-1065 .PMCID: PMC2720990.
173. Kushi LH, Doyle C, McCullough M, et al. 2012. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin, 62(1), 30-67 .PMID: 22237782.
174. Kwan ML, Kushi LH, Weltzien E, et al. 2009. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res, 11(3), R31 .PMID: 19463150.
175. Li CI, Beaber EF, Tang MT, et al. 2012. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res, 72(8), 2028-2035 .PMCID: PMC3328650.
176. Li CI, Beaber EF, Tang MT, et al. 2013a. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat, 137(2), 579-587 .PMCID: PMC3547981.
177. Li J, Humphreys K, Eriksson L, et al. 2013b. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in post-menopausal patients with breast cancer. J Clin Oncol, 31(18), 2249-2256 .PMCID: PMC3677838.
178. Li W, Ray RM, Thomas DB, et al. 2013c. Occupational exposure to magnetic fields and breast cancer among women textile workers in Shanghai, China. Am J Epidemiol, 178(7), 1038-1045 .PMCID: PMC3783098.
179. Liao DJ, and Dickson RB. 2002. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol, 80(2), 175-189 .PMID: 11897502.
180. Lichtenstein P, Holm NV, Verkasalo PK, et al. 2000. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343(2), 78-85 .PMID: 10891514.
181. Lie Fong S, Visser JA, Welt CK, et al. 2012. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab, 97(12), 4650-4655 .PMCID: PMC3683801.
182. Lindstrom S, Thompson DJ, Paterson AD, et al. 2014. Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun, 5, 5303 .PMCID: PMC4320806.
183. Lindstrom S, Vachon CM, Li J, et al. 2011. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet, 43(3), 185-187 .PMCID: PMC3076615.
184. Linos E, Spanos D, Rosner BA, et al. 2008. Effects of reproductive and demo-graphic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst, 100(19), 1352-1360 .PMCID: PMC2556703.
185. Linos E, Willett WC, Cho E, and Frazier L. 2010. Adolescent diet in relation to breast cancer risk among premenopausal women. Cancer Epidemiol Biomarkers Prev, 19(3), 689-696 .PMCID: PMC2866323.
186. Lipworth L, Tarone RE, Friis S, et al. 2009. Cancer among Scandinavian women with cosmetic breast implants: a pooled long-term follow-up study. Int J Cancer, 124(2), 490-493 .PMID: 19003966.
187. Liu R, Nelson DO, Hurley S, Hertz A, and Reynolds P. 2015. Residential exposure to estrogen disrupting hazardous air pollutants and breast cancer risk: the California Teachers Study. Epidemiology, 26(3), 365-373 .PMID: 25760782.
188. Luctkar-Flude M, Aiken A, McColl MA, and Tranmer J. 2015. A comprehensive framework and key guideline recommendations for the provision of evidence-based breast cancer survivorship care within the primary care setting. Fam Pract, 32(2), 129-140 .PMID: 25500746.
189. Luo J, Margolis KL, Wactawski-Wende J, et al. 2011. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ, 342, d1016 .PMCID: PMC3047002.
190. Luo Zc, Cheung YB, He Q, Albertsson-Wikland K, and Karlberg J. 2003. Growth in early life and its relation to pubertal growth. Epidemiology, 14(1), 65-73 .PMID: 12500048.
191. Lynch BM, Friedenreich CM, Winkler EA, et al. 2011a. Associations of objec-tively assessed physical activity and sedentary time with biomarkers of breast cancer risk in postmenopausal women: findings from NHANES (2003-2006). Breast Cancer Res Treat, 130(1), 183-194 .PMID: 21553294.
192. Lynch BM, Neilson HK, and Friedenreich CM. 2011b. Physical activity and breast cancer prevention. Recent Results Cancer Res, 186, 13-42 .PMID: 21113759.
193. Ma H, Wang Y, Sullivan-Halley J, et al. 2010. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res, 70(2), 575-587 .PMCID: PMC2807992.
194. Macon MB, and Fenton SE. 2013. Endocrine disruptors and the breast: early life effects and later life disease. J Mammary Gland Biol Neoplasia, 18(1), 43-61 .PMCID: PMC3682794.
195. Martelotto LG, Ng CK, Piscuoglio S, Weigelt B, and Reis-Filho JS. 2014. Breast cancer intra-tumor heterogeneity. Breast Cancer Res, 16(3), 210 .PMCID: PMC4053234.
196. Martin LJ, and Boyd NF. 2008. Mammographic density: potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res, 10(1), 201 .PMCID: PMC2374950.
197. Matsuno RK, Costantino JP, Ziegler RG, et al. 2011. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst, 103(12), 951-961 .PMCID: PMC3119648.
198. McCart Reed AE, Kutasovic JR, Lakhani SR, and Simpson PT. 2015. Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics.' Breast Cancer Res, 17, 12 .PMCID: PMC4310190.
199. McCormack VA, and dos Santos Silva I. 2006. Breast density and parenchymal patterns as markers of breast cancer risk: a metaanalysis. Cancer Epidemiol Biomarkers Prev, 15(6), 1159-1169 .PMID: 16775176.
200. McKenzie F, Ferrari P, Freisling H, et al. 2015. Healthy lifestyle and risk of breast cancer among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition cohort study. Int J Cancer, 136(11), 2640-2648 .PMID: 25379993.
201. McKian KP, Reynolds CA, Visscher DW, et al. 2009. Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol, 27(35), 5893-5898 .PMCID: PMC2793038.
202. Melchor L, and Benitez J. 2013. The complex genetic landscape of familial breast cancer. Hum Genet, 132(8), 845-863 .PMID: 23552954.
203. Michailidou K, Lindstrom S, Dennis J, et al. 2017. Association analysis identifies 65 new breast cancer risk loci and predicts target genes. Nat Genet, [under review].
204. Mikoczy Z, Tinnerberg H, Bjork J, and Albin M. 2011. Cancer incidence and mortality in Swedish sterilant workers exposed to ethylene oxide: updated cohort study findings 1972-2006. Int J Environ Res Public Health, 8(6), 2009-2019 .PMCID: PMC3138010.
205. Milanese TR, Hartmann LC, Sellers TA, et al. 2006. Age-related lobular invo-lution and risk of breast cancer. J Natl Cancer Inst, 98(22), 1600-1607 .PMID: 17105983.
206. Millikan R, Newman B, Tse C, et al. 2008. Epidemiology of basal- like breast cancer. Breast Cancer Res Treat, 109, 123-139 .PMCID: PMC2443103.
207. Mirick DK, Davis S, and Thomas DB. 2002. Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst, 94(20), 1578-1580 .PMID: 12381712.
208. Missmer SA, Eliassen AH, Barbieri RL, and Hankinson SE. 2004. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst, 96(24), 1856-1865 .PMID: 15601642.
209. Moore SC, Matthews CE, Ou Shu X, et al. 2016. Endogenous estrogens, estrogen metabolites, and breast cancer risk in postmenopausal Chinese women. J Natl Cancer Inst, 108(10), djw103 .PMCID: PMC4893973.
210. Morrow M, Schnitt SJ, and Norton L. 2015. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol, 12(4), 227-238 .PMID: 25622978.
211. Morton LM, Onel K, Curtis RE, Hungate EA, and Armstrong GT. 2014. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book, e57-67 .PMID: 24857148.
212. Moskowitz CS, Chou JF, Wolden SL, et al. 2014. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol, 32(21), 2217-2223 .PMCID: PMC4100937.
213. Moyer VA, and Force USPST. 2013. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 159(10), 698-708 .PMID: 24061412.
214. Muller C, Wallaschofski H, Brabant G, et al. 2014. The association between IGF-I/IGFBP-3 and subclinical end points: epidemiology faces the limits. J Clin Endocrinol Metab, 99(8), 2804-2812 .PMID: 24823454.
215. Munksgaard PS, and Blaakaer J. 2011. The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. Gynecol Oncol, 123(1), 157-163 .PMID: 21742370.
216. Munoz D, Near AM, van Ravesteyn NT, et al. 2014. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst, 106(11), dju289 .PMCID: PMC4271026.
217. Neilson HK, Friedenreich CM, Brockton NT, and Millikan RC. 2009. Physical activity and postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. Cancer Epidemiol Biomarkers Prev, 18(1), 11-27 .PMID: 19124476.
218. Nelson HD, Pappas M, Zakher B, et al. 2014. Risk assessment, genetic counsel-ing, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med, 160(4), 255-266 .PMID: 24366442.
219. Neuhouser ML, Aragaki AK, Prentice RL, et al. 2015. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women's health initiative randomized clinical trials. JAMA Oncol, 1(5), 611-621 .PMID: 26182172.
220. Nichols HB, Baird DD, Stanczyk FZ, et al. 2015a. Anti-mullerian hormone concentrations in premenopausal women and breast cancer risk. Cancer Prev Res (Phila), 8(6), 528-534 .PMCID: PMC4452465.
221. Nichols HB, DeRoo LA, Scharf DR, and Sandler DP. 2015b. Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst 107(1), dju354 .PMCID: PMC4296193.
222. Norat T, Aune D, Chan D, and Romaguera D. 2014. Fruits and vegetables: updating the epidemiologic evidence for the WCRF/AICR lifestyle recommendations for cancer prevention. Cancer Treat Res, 159, 35-50 .PMID: 24114473.
223. Norum JH, Andersen K, and Sorlie T. 2014. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. Br J Surg, 101(8), 925-938 .PMID: 24849143.
224. Nyante SJ, Sherman ME, Pfeiffer RM, et al. 2015. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst, 107(3), dju425 .PMCID: PMC4334825.
225. Oh H, Khodr ZG, Sherman ME, et al. 2016. Relation of serum estrogen metabo-lites with terminal duct lobular unit involution among women undergoing diagnostic image-guided breast biopsy. Horm Cancer, 7(5-6), 305-315 .PMCID: PMC5088060.
226. Palmer JR, Boggs DA, Wise LA, et al. 2011. Parity and lactation in to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev, 20(9), 1883-1891 .PMCID: PMC317917.
227. Palmer JR, Viscidi E, Troester MA, et al. 2014. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst, 106(10) .PMCID: PMC4271113.
228. Parise C, and Caggiano V. 2014. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California. Cancer Epidemiol, 38(5), 556-562 .PMID: 25172158.
229. Peplonska B, Stewart P, Szeszenia-Dabrowska N, et al. 2010. Occupational exposure to organic solvents and breast cancer in women. Occup Environ Med, 67(11), 722-729 .PMCID: PMC2891315.
230. Pettersson A, Graff RE, Ursin G, et al. 2014. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst, 106(5), dju078 .PMCID: PMC4568991.
231. Pfeiffer RM, Park Y, Kreimer AR, et al. 2013. Risk prediction for breast, endo-metrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med, 10(7), e1001492 .PMCID: PMC3728034.
232. Phipps AI, Buist DS, Malone KE, et al. 2011a. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control, 22(3), 399-405 .PMCID: PMC3042513.
233. Phipps AI, Chlebowski RT, Prentice R, et al. 2011b. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev, 20(3), 454-63 .PMCID: PMC3064558.
234. Pike MC, Krailo MD, Henderson BE, Casagrande JT, and Hoel DG. 1983. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature, 303(5920), 767-770 .PMID: 6866078.
235. Pirie K, Beral V, Peto R, et al. 2008. Passive smoking and breast cancer in never smokers: prospective study and meta-analysis. Int J Epidemiol, 37(5), 1069-1079 .PMID: 18544575.
236. Pollak M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8(12), 915-928 .PMID: 19029956.
237. Ponder BA, Antoniou A, Dunning A, Easton DF, and Pharoah PD. 2005. Polygenic inherited predisposition to breast cancer. Cold Spring Harb Symp Quant Biol, 70, 35-41 .PMID: 16869736.
238. Portschy PR, Abbott AM, Burke EE, et al. 2015. Perceptions of contralateral breast cancer risk: a prospective, longitudinal study. Ann Surg Oncol, 22(12), 3846-3852 .PMID: 25762480.
239. Press DJ, Sullivan-Halley J, Ursin G, et al. 2011. Breast cancer risk and ovariec-tomy, hysterectomy, and tubal sterilization in the women's contraceptive and reproductive experiences study. Am J Epidemiol, 173(1), 38-47 .PMCID: PMC3025644.
240. Price ER, Hargreaves J, Lipson JA, et al. 2013. The California breast density information group: a collaborative response to the issues of breast density, breast cancer risk, and breast density notification legislation. Radiology, 269(3), 887-892 .PMID: 24023072.
241. Protani M, Coory M, and Martin JH. 2010. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat, 123(3), 627-635 .PMID: 20571870.
242. Quante AS, Whittemore AS, Shriver T, Strauch K, and Terry MB. 2012. Breast cancer risk assessment across the risk continuum: genetic and nonge- netic risk factors contributing to differential model performance. Breast Cancer Res, 14(6), R144 .PMCID: PMC4053132.
243. Ravdin PM, Cronin KA, Howlader N, et al. 2007. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 356(16), 1670-1674 .PMID: 17442911.
244. Reigstad MM, Larsen IK, Myklebust TA, et al. 2015. Risk of breast cancer fol-lowing fertility treatment-- a registry based cohort study of parous women in Norway. Int J Cancer, 136(5), 1140-1148 .PMCID: PMC4268160.
245. Renehan AG, Tyson M, Egger M, Heller RF, and Zwahlen M. 2008. Body- mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 371(9612), 569-578 .PMID: 18280327.
246. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, and Colditz GA. 2001. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst, 93(5), 358-366 .PMID: 11238697.
247. Romieu I, Scoccianti C, Chajes V, et al. 2015. Alcohol intake and breast cancer in the European prospective investigation into cancer and nutrition. Int J Cancer, 137(8), 1921-1930 .PMID: 25677034.
248. Rosebrock A, Caban JJ, Figueroa J, et al. 2013. Quantitative analysis of TDLUs using adaptive morphological shape techniques. Proc SPIE Int Soc Opt Eng, vol.8676. PMCID: PMC4339025.
249. Rosenberg L, Palmer JR, Bethea TN, et al. 2014. A prospective study of physical activity and breast cancer incidence in African-American women. Cancer Epidemiol Biomarkers Prev, 23(11), 2522-2531. PMCID: PMC4221421.
250. Rosenberg PS, Barker KA, and Anderson WF. 2015. Estrogen receptor status and the future burden of invasive and in situ breast cancers in the United States. J Natl Cancer Inst, 107(9), djv159. PMID: 26063794.
251. Rosenfeld RG. 2003. Insulin-like growth factors and the basis of growth. N Engl J Med, 349(23), 2184-2186. PMID: 14657423.
252. Rowzee AM, Lazzarino DA, Rota L, Sun Z, and Wood TL. 2008. IGF ligand and receptor regulation of mammary development. J Mammary Gland Biol Neoplasia, 13(4), 361-370. PMCID: PMC2665296.
253. Russo J, Hu YF, Yang X, and Russo IH. 2000. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr 27, 17-37. PMID: 10963618.
254. Russo J, and Russo IH. 2004. Development of the human breast. Maturitas, 49(1), 2-15. PMID: 15351091.
255. Said SM, Rizzo W, Degnim AC, et al. 2014. Risk of developing breast cancer in patients with flat epithelial atypia (FEA) in benign breast biopsies. Modern Pathology, 27 (Supp 2s) USCAP 103, 79A.
256. Santen RJ, and Mansel R. 2005. Benign breast disorders. N Engl J Med, 353(3), 275-285. PMID: 16034013.
257. Saxena T, Lee E, Henderson KD, et al. 2010. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev, 19(9), 2366-2378. PMCID: PMC2936672.
258. Schernhammer ES, Tworoger SS, Eliassen AH, et al. 2007. Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer, 14(3), 721-732. PMID: 17914102. SEER. 2015. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2013) (www.seer.cancer.gov/popdata), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released January 2015.
259. Seitz HK, Pelucchi C, Bagnardi V, and La Vecchia C. 2012. Epidemiology and pathophysiology of alcohol and breast cancer: update 2012. Alcohol Alcohol, 47(3), 204-212. PMID: 22459019.
260. Sexton KR, Franzini L, Day RS, et al. 2011. A review of body size and breast cancer risk in Hispanic and African American women. Cancer, 117(23), 5271-5281. PMID: 21598244.
261. Shafrir AL, Zhang X, Poole EM, Hankinson SE, and Tworoger SS. 2014. The association of reproductive and lifestyle factors with a score of multiple endogenous hormones. Horm Cancer, 5(5), 324-335. PMCID: PMC4167477.
262. Shen D, Mao W, Liu T, et al. 2014. Sedentary behavior and incident cancer: a meta-analysis of prospective studies. PLoS One, 9(8), e105709. PMCID: PMC4143275.
263. Sherman ME, Mies C, and Gierach GL. 2014. Opportunities for molecular epidemiological research on ductal carcinoma in-situ and breast carci-nogenesis: interdisciplinary approaches. Breast Dis, 34(3), 105-116. PMCID: PMC4558907.
264. Sickles EA, D'Orsi CJ, Bassett LW, et al. 2013. ACR BiRADS Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology.
265. Siegel RL, Miller KD, and Jemal A. 2015. Cancer statistics, 2015. CA Cancer J Clin, 65(1), 5-29. PMID: 25559415.
266. Siiteri PK. 1987. Adipose tissue as a source of hormones. Am J Clin Nutr, 45(1), 277-282. PMID: 3541569.
267. Sineshaw HM, Gaudet M, Ward EM, et al. 2014. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011). Breast Cancer Res Treat, 145(3), 753-763. PMID: 24794028.
268. Soini T, Hurskainen R, Grenman S, et al. 2014. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol, 124(2 Pt 1), 292-299. PMID: 25004338.
269. Sowers MR, Eyvazzadeh AD, McConnell D, et al. 2008. Anti-mulle- rian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab, 93(9), 3478-3483. PMCID: PMC2567855.
270. Stone J, Thompson DJ, Dos Santos Silva I, et al. 2015. Novel associations between common breast cancer susceptibility variants and risk-predicting mammographic density measures. Cancer Res, 75(12), 2457-2467. PMCID: PMC4470785.
271. Strom BL, Berlin JA, Weber AL, et al. 2004. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception, 69(5), 353-360. PMID: 15105056.
272. Su HY, and Cheng WT. 2004. Increased milk yield in transgenic mice expressing insulin-like growth factor 1. Anim Biotechnol, 15(1), 9-19. PMID: 15248597.
273. Sun X, Gierach GL, Sandhu R, et al. 2013. Relationship of mammographic density and gene expression: analysis of normal breast tissue surrounding breast cancer. Clin Cancer Res, 19(18), 4972-4982. PMCID: PMC4073678.
274. Sun X, Sandhu R, Figueroa JD, et al. 2014. Benign breast tissue composition in breast cancer patients: association with risk factors, clinical variables, and gene expression. Cancer Epidemiol Biomarkers Prev, 23(12), 2810-2818. PMCID: PMC4278568.
275. Suzuki R, Orsini N, Saji S, Key TJ, and Wolk A. 2009. Body weight and inci-dence of breast cancer defined by estrogen and progesterone receptor status: a meta-analysis. Int J Cancer, 124(3), 698-712. PMID: 18988226.
276. Takkouche B, Etminan M, and Montes-Martinez A. 2005. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA, 293(20), 2516-2525. PMID: 15914752.
277. Takkouche B, Regueira-Mendez C, and Etminan M. 2008. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst, 100(20), 1439-1447. PMID: 18840819.
278. Tamimi RM, Colditz GA, Hazra A, et al. 2012. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat, 131(1), 159-167. PMCID: PMC3237947.
279. Thomson CA, McCullough ML, Wertheim BC, et al. 2014. Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative. Cancer Prev Res (Phila), 7(1), 42-53. PMCID: PMC4090781.
280. Tice JA, Cummings SR, Smith-Bindman R, et al. 2008. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med, 148(5), 337-347. PMCID: PMC2674327.
281. Tice JA, Cummings SR, Ziv E, and Kerlikowske K. 2005. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat, 94(2), 115-122. PMID: 16261410.
282. Tice JA, Miglioretti DL, Li CS, et al. 2015. Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol, 33(28), 3137-3143. PMCID: PMC4582144.
283. Tikk K, Sookthai D, Johnson T, et al. 2014. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Ann Oncol, 25(7), 1422-1428. PMID: 24718887.
284. Titus-Ernstoff L, Hatch EE, Hoover RN, et al. 2001. Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. Br J Cancer, 84(1), 126-133. PMCID: PMC2363605.
285. Torre LA, Bray F, Siegel RL, et al. 2015. Global cancer statistics, 2012. CA Cancer J Clin, 65(2), 87-108. PMID: 25651787.
286. Trabert B, Falk RT, Stanczyk FZ, et al. 2015. Reproducibility of a novel assay to measure serum progesterone pathway metabolites using liquid chroma- tography-tandem mass spectrometry. Horm Molec Biol Clin Invest, 23(3), 79-84. PMCID: PMC4966666.
287. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, and Ioannidis JP. 2015. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ, 350, g7607. PMID: 25555821.
288. Tworoger SS, Eliassen AH, Zhang X, et al. 2013. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res, 73(15), 4810-4819. PMCID: PMC3738582.
289. Tworoger SS, Rice MS, Rosner BA, et al. 2015. Bioactive prolactin levels and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev, 24(1), 73-80. PMCID: PMC4294963.
290. Tworoger SS, Zhang X, Eliassen AH, et al. 2014. Inclusion of endogenous hor-mone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol, 32(28), 3111-3117. PMCID: PMC4171356.
291. Tyrer J, Duffy SW, and Cuzick J. 2004. A breast cancer prediction model incor-porating familial and personal risk factors. Stat Med, 23(7), 1111-1130. PMID: 15057881.
292. US Department of Health and Human Services. 2014. The Health Consequences of Smoking: 50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
293. Ursin G, Lillie EO, Lee E, et al. 2009. The relative importance of genetics and environment on mammographic dnsity. Cancer Epidemiol Biomarkers Prev, 18(1), 102-112. PMID: 19124487.
294. Vachon CM, Pankratz VS, Scott CG, et al. 2015. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst, 107(5). PMID: 25745020.
295. Vachon CM, Scott CG, Fasching PA, et al. 2012. Common breast cancer sus-ceptibility variants in LSP1 and RAD51L1 are associated with mam- mographic density measures that predict breast cancer risk. Cancer Epidemiol Biomarkers Prev, 21(7), 1156-1166. PMCID: PMC3569092.
296. Venkitaraman R. 2010. Lobular neoplasia of the breast. Breast J, 16(5), 519-528. PMID: 20701604.
297. Vera-Ramirez L, Ramirez-Tortosa MC, Sanchez-Rovira P, et al. 2013. Impact of diet on breast cancer risk: a review of experimental and observational studies. Crit Rev Food Sci Nutr, 53(1), 49-75. PMID: 23035920.
298. Verheus M, Peeters PH, Rinaldi S, et al. 2006. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer, 119(3), 659-667. PMID: 16572422.
299. Verma S, Miles D, Gianni L, et al. 2012. Trastuzumab emtansine for HER2- positive advanced breast cancer. N Engl J Med, 367(19), 1783-1791. PMID: 23020162.
300. Villeneuve S, Fevotte J, Anger A, et al. 2011. Breast cancer risk by occupation and industry: analysis of the CECILE study, a population-based case-con- trol study in France. Am J Ind Med, 54(7), 499-509. PMID: 21472744.
301. Virnig BA, Wang SY, Shamilyan T, Kane RL, and Tuttle TM. 2010. Ductal carcinoma in situ: risk factors and impact of screening. J Natl Cancer Inst Monogr, 2010(41), 113-116. PMID: 20956813.
302. Visser JA, Schipper I, Laven JS, and Themmen AP. 2012. Anti-Mullerian hor-mone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol, 8(6), 331-341. PMID: 22231848.
303. Visvader JE, and Stingl J. 2014. Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev, 28(11), 1143-1158. PMCID: PMC4052761.
304. Visvanathan K, Hurley P, Bantug E, et al. 2013. Use of pharmacologic inter-ventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 31(23), 2942-2962. PMID: 23835710.
305. Vogel VG, Costantino JP, Wickerham DL, et al. 2010. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila), 3(6), 696-706. PMCID: PMC2935331.
306. Vrieling A, Buck K, Kaaks R, and Chang-Claude J. 2010. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat, 123(3), 641-649. PMID: 20711809.
307. Wang J, Lee IM, Tworoger SS, et al. 2015. Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-analysis. Cancer Epidemiol Biomarkers Prev, 24(8), 1199-1206. PMCD: PMC4526401.
308. Warwick J, Birke H, Stone J, et al. 2014. Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Res, 16(5), 451. PMCID: PMC4303130.
309. WCRF/AICR. 2008. WCRF/AICR Systematic Literature Review Continuous Update Report: The Associations Between Food, Nutrition and Physical Activity and the Risk of Breast Cancer. London: Imperial College.
310. WCRF/AICR. 2014. Diet, Nutrition, Physical Activity, and Breast Cancer Survivors. World Cancer Research Fund International/American Institute for Cancer Research Continuous Update Project Report. London: World Cancer Research Fund International.
311. Weaver DL, Rosenberg RD, Barlow WE, et al. 2006. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer, 106(4), 732-742. PMID: 16411214.
312. Weigelt B, Geyer FC, and Reis-Filho JS. 2010. Histological types of breast cancer: how special are they? Mol Oncol, 4(3), 192-208. PMID: 20452298.
313. Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, and Offit K. 2011. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin, 61(5), 327-359. PMCID: PMC3346864.
314. Welch HG, and Black WC. 1997. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med, 127(11), 1023-1028. PMID: 9412284.
315. Welsh AW, Moeder CB, Kumar S, et al. 2011. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol, 29(22), 2978-2984. PMCID: PMC3157961.
316. Wiebe JP. 2006. Progesterone metabolites in breast cancer. Endocr Relat Cancer, 13(3), 717-738. PMID: 16954427.
317. Wiebe JP, Beausoleil M, Zhang G, and Cialacu V. 2010. Opposing actions of the progesterone metabolites, 5alpha-dihydroprogesterone (5alphaP) and 3alpha-dihydroprogesterone (3alphaHP) on mitosis, apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines. J Steroid Biochem Mol Biol, 118(1-2), 125-132. PMID: 19931389.
318. Wiebe JP, and Lewis MJ. 2003. Activity and expression of progesterone metab-olizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, mDa-MB-231, T-47d) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer, 3, 9. PMCID: PMC154104.
319. Work ME, Reimers LL, Quante AS, et al. 2014. Changes in mammographic density over time in breast cancer cases and women at high risk for breast cancer. Int J Cancer, 135(7), 1740-1744. PMCID: PMC4107003.
320. World Health Organization. 2003. World Health Organization Classification of Tumors. 3rd ed. Lyon: IARC Press.
321. World Health Organization. 2012. World Health Organization Classification of Tumors of the Breast. 4th ed. Lyon: IARC Press.
322. Wu Y, Zhang D, and Kang S. 2013. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat, 137(3), 869-882. PMID: 23274845.
323. Xue F, and Michels KB. 2007. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol, 8(12), 1088-1100. PMID: 18054879.
324. Xue F, Willett WC, Rosner BA, Hankinson SE, and Michels KB. 2011. Cigarette smoking and the incidence of breast cancer. Arch Intern Med, 171(2), 125-133. PMCID: PMC3131146.
325. Yaffe M. 2008. Mammographic density: measurement of mammographic density. Breast Cancer Res, 10(3), 209. PMCID: PMC2481498.
326. Yager JD, and Davidson NE. 2006. Estrogen carcinogenesis in breast cancer. N Engl J Med, 354(3), 270-282. PMID: 16421368.
327. Yaghjyan L, Colditz GA, Collins LC, et al. 2011. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst, 103(15), 1179-1189. PMCID: PMC3149043.
328. Yang XR, Chang-Claude J, Goode EL, et al. 2011. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst, 103(3), 250-263. PMCID: PMC3107570.
329. Yang XR, Sherman ME, Rimm DL, et al. 2007. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev, 16(3), 439-443. PMID: 17372238.
330. Yang Y, Zhang F, Skrip L, Wang Y, and Liu S. 2013. Lack of an association between passive smoking and incidence of female breast cancer in non-smokers: evidence from 10 prospective cohort studies. PLoS One, 8(10), e77029. PMCID: PMC3800073.
331. Zhang X, Tworoger SS, Eliassen AH, and Hankinson SE. 2013. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow- up. Breast Cancer Res Treat, 137(3), 883-892. PMCID: PMC3582409.
332. Zheng W, Zhang B, Cai Q, et al. 2013. Common genetic determinants of breast- cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Hum Mol Genet, 22(12), 2539-2550. PMCID: PMC3658167.
333. Zhou Y, Zhao H, and Peng C. 2015. Association of sedentary behavior with the risk of breast cancer in women: update meta-analysis of observational studies. Ann Epidemiol, 25(9), 687-697. PMID: 26099193.
334. Ziegler RG, Fuhrman BJ, Moore SC, and Matthews CE. 2015. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids, 99(Pt A), 67-75